跳至主要内容
临床试验/NCT03563326
NCT03563326Unknown1 期

Clinical Trial of Intraperitoneal CAR-T Cells Infusion for the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis

Jian-Kun Hu1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2018年8月30日最近更新:
适应症
干预措施

试验速览

阶段
1 期
发起方
入组人数
40
试验地点
1
主要终点
EpCAM CAR-T cells treatment related adverse events

研究概览

简要总结

To investigate the safety and efficacy of intraperitoneal infusion of EpCAM CAR-T cell in advanced gastric cancer with peritoneal metastasis by a prospective nonrandomized controlled trial.

详细描述

Chimeric antigen receptor modified T (CAR-T) cells have the capability in targeting and recognizing tumor antigen, and can specifically recognize, bind and kill tumor cells with positive antigen. Through local drug delivery, CAR-T cells have successfully achieved remarkable effect to treat solid tumors. Gastric cancer is one of the most frequent malignant tumors with high mortality, especially in China. Peritoneal metastasis is one of the common routes of metastasis. Once peritoneal metastasis occurred, patients should be categorized as clinical pathological stage IV with extremely poor prognosis, and the effect of routine treatments would be unsatisfactory. Epithelial cell adhesion molecule (EpCAM) is highly expressed in gastric cancer cells and closely associated with the poor prognosis of patients. In our previous pre-clinical research researches, the investigators have obtained CAR-T cells targeting EpCAM (EpCAM CAR-T), and finished the preparations of cells which could be used in clinical practice. Based on our previous works, the investigators aim to investigate the safety and efficacy of peritoneal infusion of EpCAM CAR-T cell in advanced gastric cancer with peritoneal metastasis by a prospective nonrandomized controlled trial. The results of this clinical trial are expected to provide the new treatment strategy for gastric cancer patients with peritoneal metastasis.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with EpCAM positive gastric cancer who have peritoneal metastasis at first visit; Patients with highly suspected or previous proven peritoneal metastasis by biopsy, CT, digital rectal examination, etc. who failed to the routine therapies like chemotherapy;
  • Age between 18 and 75;
  • Estimated survival time is longer than 3 months;
  • Eastern Cooperative Oncology Group (ECOG)scores 0-2;
  • Hemoglobin≥90g/L, ANC≥1.5×109/L, PLT≥80×109/L;
  • Negative pregnancy test for child-bearing period; both male and female patients should agree to apply effective contraceptive methods in the period of treatment and one year after treatment;
  • Both patients and families totally understand the objectives and risks of the treatments and sign the informed consent.

排除标准

  • Comorbidity with other diseases treated by immunosuppressive drugs or steroids therapy systematically;
  • Uncontrolled active infection;
  • HIV positive;
  • Active hepatic B or C virus infection, active tuberculosis;
  • Pregnant or lactation female;
  • Disagree to apply effective contraceptive methods in the period of treatment and one year after treatment;
  • Positive cytology examination alone.

研究组 & 干预措施

CAR-T cell and chemotherapy

Experimental

Biological: CAR-T cells targeting EpCAM Chemotherapy: determined by medical Oncologist

干预措施: CAR-T cells targeting EpCAM (Biological)

CAR-T cell and chemotherapy

Experimental

Biological: CAR-T cells targeting EpCAM Chemotherapy: determined by medical Oncologist

干预措施: Chemotherapy (Biological)

chemotherapy

Active Comparator

Chemotherapy: determined by medical Oncologist

干预措施: Chemotherapy (Biological)

结局指标

主要结局

EpCAM CAR-T cells treatment related adverse events

时间窗: 4 weeks

Adverse events after receiving EpCAM CAR-T cells treatment, according to NCI-CTCAE v4.0.

次要结局

  • Overall survival outcome(2 years)
  • Metabolism kinetics of CAR-T cells(2 years)
  • Progress free survival outcome(2 years)

研究者

发起方
Jian-Kun Hu
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Jian-Kun Hu

Vice director of Gastrointestinal Surgery department, West China Hospital; Director of Institute of Gastric Cancer, State Key Laboratory of Biotherapy, West China Hospital

West China Hospital

研究点 (1)

Loading locations...

相似试验